Lycopene – Just Another Bust!
A group of investigators, interested in the influence of lycopene on both the clinical and laboratory progression of advanced prostate cancer in men with hormone refractory prostate cancer, ran a small prospective Phase II pilot [...]
Scott Goodwin Completes His 5th Chemotherapy Session
How does the song go- "Suddenly, I'm not half the man I used to be.” That is a feeling that I have experienced and that I believe we all will experience. Nevertheless, we have to [...]
Additional Information On Yesterday’s Post About Alpharadin
Charles (Chuck) Maack, Prostate Cancer Advocate/Mentor from the Wichita Kansas Chapter of Us TOO sent me this follow-up to yesterday's post on Alpharadin. Interesting is this drug completed Phase II trials in Norway back in [...]
Algeta, Completing A Successful Phase II Trial For Men With Bone Metastases Will Begin Enrolling US Survivors Into A Phase III Trial
Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases [...]
Thalidomide and Intermittent ADT Effects PSA Progression
According to a study reported in the Journal of Urology, Thalidomide is associated with an increase in prostate specific antigen (PSA) progression-free survival in men with biochemically recurrent prostate cancer who are on intermittent androgen [...]
A Clinical Trial : Ixabepilone, Mitoxantrone, and Prednisone in Treating Patients with Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy and Chemotherapy
I was recently reviewing current clinical trials and came across this one for men who have failed chemotherapy, what many of us view as the final treatment for advanced prostate cancer. It provides a potential [...]